repotrectinib, ROS1/TRK/ALK tyrosine kinase inhibitor, oral, brain-penetrant inhibitor of multiple cancer-driving tyrosine kinases, granted three Breakthrough Therapy Designations from the FDA, acquired by BMS from Turning Point Therapeutics in $4.1B deal

Why Did Bristol Myers Squibb (BMS) Pay $4.1 Billion for Turning Point Therapeutics?

Turning Point Therapeutics ($TPTX) was recently acquired by BMS for a whopping $4.1 billion in cash. Turning Point’s most…

8 mins read

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

Newsletter

Molecules of the Month

    molecule of the day

    AZD0364 – December

    oral reversible ERK1/2 kinase inhibitor

    combo eff. w/ MEKi in mKRAS model; in Ph. I

    from historical kinase sel. data, SBDD + opt.

    Mol. Cancer Ther. Dec. 3, 2020

    AstraZeneca, Cambridge, UK

    hall of fame: past molecules of the month

    Check out previous entries below.

    past molecules of the year nominees

    Check out previous nominees below.

    past molecules of the year

    Check out previous selections below.

    Profile photo of Julien Lefranc

    Julien Lefranc

    Oncology Drug Discovery and Degraders

    Christian Kuttruff

    Respiratory Disease & Business Development

    Portrait image of Callie Bryan

    Callie Bryan

    Immunology & Kinase Drug Discovery

    View All

    Join the Drug Hunter mailing list

    to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

    Newsletter

    Join Subscribers from

    …and hundreds more!